Amendment and Response to Restriction Requirement U.S. Patent Application Serial No. 10/650,110 Page 2

RECEIVED CENTRAL FAX CENTER UCT 2 0 2006

## AMENDMENTS TO THE CLAIMS

This listing of the claims will replace all prior versions, and listings, of claims in the application:

- 1-6 (Cancelled)
- 7. (Original) A method for treating Alzheimer disease in a patient diagnosed with Alzheimer disease comprising:

administration of an effective amount of one or more partially delipidated protein particles, one or more partially delipidated lipoprotein particles or a combination thereof, wherein the amount is effective to treat Alzheimer disease in the patient.

8. (Original) A method for preventing or delaying the onset of Alzheimer disease in a patient at risk of developing Alzheimer disease comprising:

administration of an effective amount of one or more partially delipidated protein particles, one or more partially delipidated lipoprotein particles or a combination thereof, wherein the amount is effective to prevent or delay the onset of Alzheimer disease in the patient.

- 9. (Original) The method of Claim 7, wherein the one or more partially delipidated lipoprotein particles is HDL, LDL or VLDL, or a combination thereof.
- 10. (Original) The method of Claim 8, wherein the one or more partially delipidated lipoprotein particles is HDL, LDL or VLDL, or a combination thereof.
- 11. (Original) The method of Claim 7, wherein the method reduces amyloid plaque, decreases neurofibrillary tangles, reduces levels of Aβ, alters a ratio of Aβ40 to Aβ42, affects enzymatic processing of APP, or reduces levels of phosphorylated tau protein.

US2000 9547599 1

Amendment and Response to Restriction Requirement U.S. Patent Application Serial No. 10/650,110 Page 3

- 12. (Original) The method of Claim 8, wherein the method reduces amyloid plaque, decreases neurofibrillary tangles, reduces levels of A $\beta$ , alters a ratio of A $\beta$ 40 to A $\beta$ 42, affects enzymatic processing of APP, or reduces levels of phosphorylated tau protein.
- 13. (Original) The method of Claim 7, further comprising administration of a therapeutic agent, wherein the therapeutic agent is an agent that affects lipid metabolism or is an agent that affects parameters associated with Alzheimer disease.
- 14. (Original) The method of Claim 8, further comprising administration of a therapeutic agent, wherein the therapeutic agent is an agent that affects lipid metabolism or is an agent that affects parameters associated with Alzheimer disease.
- 15. (Currently Amended) The method of Claim 13, wherein the therapeutic agent is [a] selected from the group consisting of synthetic HDL compositions, compositions selectively enhancing HDL function with minimal effect on LDL levels, cholesteryl ester transfer protein inhibitors, cholesterol level lowering agents and triglyceride level lowering agents in a pharmaceutically acceptable vehicle, and combinations thereof.
- 16. (Currently Amended) The method of Claim 14, wherein the therapeutic agent is [a] selected from the group consisting of synthetic HDL compositions, compositions selectively enhancing HDL function with minimal effect on LDL levels, cholesteryl ester transfer protein inhibitors, cholesterol level lowering agents and triglyceride level lowering agents in a pharmaceutically acceptable vehicle, and combinations thereof.